Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice

Junzo Kamei, Midori Sodeyama, Makoto Tsuda, Tsutomu Suzuki, Hiroshi Nagase

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The antinociceptive effect of buprenorphine was examined in μ1-opioid receptor-deficient CXBK mice. I.p. administration of buprenorphine at a dose of 3 mg/kg produced marked antinociception in the tail-flick test in C57BL/6 mice, a progenitor strain of CXBK mice. The antinociceptive effect of buprenorphine in C57BL/6 mice was antagonized by pretreatment with either β- funaltrexamine (β-FNA), a μ-opioid receptor antagonist, or naloxonazine (NXZ), a selective μ-opioid receptor antagonist. The antinociceptive effect of buprenorphine (3 mg/kg, i.p.) in CXBK mice was significantly less than that in C57BL/6 mice. Neither β-FNA nor NXZ reduced the antinociceptive effect of buprenorphine in CXBK mice. There was no significant difference between the buprenorphine-induced antinociceptive effect in CXBK mice and NXZ-treated C57BL/6 mice. Furthermore, neither naltrindole, a selective δ- opioid receptor antagonist, norbinaltorphimine, a selective κ-opioid receptor antagonist, had a significant effect on the antinociceptive effects of buprenorphine in both CXBK and C57BL/6 mice. These results support our previous hypothesis that μ1- rather than μ2-, δ- or κ-opioid receptors are involved in the antinociceptive effects of buprenorphine.

Original languageEnglish
JournalLife Sciences
Volume60
Issue number22
DOIs
Publication statusPublished - Apr 25 1997
Externally publishedYes

Fingerprint

Buprenorphine
Opioid Receptors
Inbred C57BL Mouse
Narcotic Antagonists
naltrindole
Tail

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice. / Kamei, Junzo; Sodeyama, Midori; Tsuda, Makoto; Suzuki, Tsutomu; Nagase, Hiroshi.

In: Life Sciences, Vol. 60, No. 22, 25.04.1997.

Research output: Contribution to journalArticle

Kamei, Junzo ; Sodeyama, Midori ; Tsuda, Makoto ; Suzuki, Tsutomu ; Nagase, Hiroshi. / Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice. In: Life Sciences. 1997 ; Vol. 60, No. 22.
@article{14ce5a633c5c472b80aa15bf71ef8cf8,
title = "Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice",
abstract = "The antinociceptive effect of buprenorphine was examined in μ1-opioid receptor-deficient CXBK mice. I.p. administration of buprenorphine at a dose of 3 mg/kg produced marked antinociception in the tail-flick test in C57BL/6 mice, a progenitor strain of CXBK mice. The antinociceptive effect of buprenorphine in C57BL/6 mice was antagonized by pretreatment with either β- funaltrexamine (β-FNA), a μ-opioid receptor antagonist, or naloxonazine (NXZ), a selective μ-opioid receptor antagonist. The antinociceptive effect of buprenorphine (3 mg/kg, i.p.) in CXBK mice was significantly less than that in C57BL/6 mice. Neither β-FNA nor NXZ reduced the antinociceptive effect of buprenorphine in CXBK mice. There was no significant difference between the buprenorphine-induced antinociceptive effect in CXBK mice and NXZ-treated C57BL/6 mice. Furthermore, neither naltrindole, a selective δ- opioid receptor antagonist, norbinaltorphimine, a selective κ-opioid receptor antagonist, had a significant effect on the antinociceptive effects of buprenorphine in both CXBK and C57BL/6 mice. These results support our previous hypothesis that μ1- rather than μ2-, δ- or κ-opioid receptors are involved in the antinociceptive effects of buprenorphine.",
author = "Junzo Kamei and Midori Sodeyama and Makoto Tsuda and Tsutomu Suzuki and Hiroshi Nagase",
year = "1997",
month = "4",
day = "25",
doi = "10.1016/S0024-3205(97)00170-7",
language = "English",
volume = "60",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "22",

}

TY - JOUR

T1 - Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice

AU - Kamei, Junzo

AU - Sodeyama, Midori

AU - Tsuda, Makoto

AU - Suzuki, Tsutomu

AU - Nagase, Hiroshi

PY - 1997/4/25

Y1 - 1997/4/25

N2 - The antinociceptive effect of buprenorphine was examined in μ1-opioid receptor-deficient CXBK mice. I.p. administration of buprenorphine at a dose of 3 mg/kg produced marked antinociception in the tail-flick test in C57BL/6 mice, a progenitor strain of CXBK mice. The antinociceptive effect of buprenorphine in C57BL/6 mice was antagonized by pretreatment with either β- funaltrexamine (β-FNA), a μ-opioid receptor antagonist, or naloxonazine (NXZ), a selective μ-opioid receptor antagonist. The antinociceptive effect of buprenorphine (3 mg/kg, i.p.) in CXBK mice was significantly less than that in C57BL/6 mice. Neither β-FNA nor NXZ reduced the antinociceptive effect of buprenorphine in CXBK mice. There was no significant difference between the buprenorphine-induced antinociceptive effect in CXBK mice and NXZ-treated C57BL/6 mice. Furthermore, neither naltrindole, a selective δ- opioid receptor antagonist, norbinaltorphimine, a selective κ-opioid receptor antagonist, had a significant effect on the antinociceptive effects of buprenorphine in both CXBK and C57BL/6 mice. These results support our previous hypothesis that μ1- rather than μ2-, δ- or κ-opioid receptors are involved in the antinociceptive effects of buprenorphine.

AB - The antinociceptive effect of buprenorphine was examined in μ1-opioid receptor-deficient CXBK mice. I.p. administration of buprenorphine at a dose of 3 mg/kg produced marked antinociception in the tail-flick test in C57BL/6 mice, a progenitor strain of CXBK mice. The antinociceptive effect of buprenorphine in C57BL/6 mice was antagonized by pretreatment with either β- funaltrexamine (β-FNA), a μ-opioid receptor antagonist, or naloxonazine (NXZ), a selective μ-opioid receptor antagonist. The antinociceptive effect of buprenorphine (3 mg/kg, i.p.) in CXBK mice was significantly less than that in C57BL/6 mice. Neither β-FNA nor NXZ reduced the antinociceptive effect of buprenorphine in CXBK mice. There was no significant difference between the buprenorphine-induced antinociceptive effect in CXBK mice and NXZ-treated C57BL/6 mice. Furthermore, neither naltrindole, a selective δ- opioid receptor antagonist, norbinaltorphimine, a selective κ-opioid receptor antagonist, had a significant effect on the antinociceptive effects of buprenorphine in both CXBK and C57BL/6 mice. These results support our previous hypothesis that μ1- rather than μ2-, δ- or κ-opioid receptors are involved in the antinociceptive effects of buprenorphine.

UR - http://www.scopus.com/inward/record.url?scp=0342618303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342618303&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(97)00170-7

DO - 10.1016/S0024-3205(97)00170-7

M3 - Article

C2 - 9180346

AN - SCOPUS:0342618303

VL - 60

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 22

ER -